Syndeio Biosciences
Syndeio Biosciences Appoints Aaron Koenig, M.D., as Chief Medical Officer (CMO)
Syndeio Biosciences; Aaron Koenig; Chief Medical Officer; CNS disorders; synaptic health; neuroscience drug development; zelquistinel; Alzheimer’s disease; neuropsychiatric; clinical trials